pGEX-5X-3-SARS-CoV-2-3CL Citations (3)
Originally described in: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.Iketani S, Forouhar F, Liu H, Hong SJ, Lin FY, Nair MS, Zask A, Huang Y, Xing L, Stockwell BR, Chavez A, Ho DD Nat Commun. 2021 Apr 1;12(1):2016. doi: 10.1038/s41467-021-22362-2. PubMed Journal
Articles Citing pGEX-5X-3-SARS-CoV-2-3CL
| Articles |
|---|
| Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. Hirose Y, Shindo N, Mori M, Onitsuka S, Isogai H, Hamada R, Hiramoto T, Ochi J, Takahashi D, Ueda T, Caaveiro JMM, Yoshida Y, Ohdo S, Matsunaga N, Toba S, Sasaki M, Orba Y, Sawa H, Sato A, Kawanishi E, Ojida A. J Med Chem. 2022 Oct 27;65(20):13852-13865. doi: 10.1021/acs.jmedchem.2c01081. Epub 2022 Oct 13. PubMed |
| Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening. Liu H, Zask A, Forouhar F, Iketani S, Williams A, Vaz DR, Habashi D, Choi K, Resnick SJ, Hong SJ, Lovett DH, Bai T, Chavez A, Ho DD, Stockwell BR. Nat Commun. 2025 Jan 2;16(1):152. doi: 10.1038/s41467-024-55421-5. PubMed |
A multiplex method for rapidly identifying viral protease inhibitors.
Hong SJ, Resnick SJ, Iketani S, Cha JW, Albert BA, Fazekas CT, Chang CW, Liu H, Dagan S, Abagyan MR, Fajtova P, Culbertson B, Brace B, Reddem ER, Forouhar F, Glickman JF, Balkovec JM, Stockwell BR, Shapiro L, O'Donoghue AJ, Sabo Y, Freundlich JS, Ho DD, Chavez A.
Mol Syst Biol. 2025 Feb;21(2):158-172. doi: 10.1038/s44320-024-00082-1. Epub 2025 Jan 6.
PubMed
Associated Plasmids |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.